✨ Free AI Report
McKesson Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research McKesson Corporation
Company Research

McKesson Corporation: Business Overview, Financials & Competitive Analysis

McKesson Corporation scores 8/10 on the AskCyborg Cyborg Score (Strong). Structural re-rating from cyclical distributor to specialty pharma/oncology play with superior margins and duopoly pricing power. McKesson demonstrates exceptional execution with Q3 FY2026 EPS beating expectations ($9.34 vs $9.27), raised full-year guidance ($38.80-$39.20), and 48% stock outperformance over 12 months. The company's 41% market share, clinical-to-distribution pipeline, and 85%+ institutional.

What is McKesson Corporation's industry? McKesson Corporation (mckesson.com) operates in Pharmaceutical & Medical Distribution; Healthcare Services. AskCyborg classifies McKesson Corporation under Pharmaceutical & Medical Distribution; Healthcare Services in its company registry.

McKesson is America's leading pharmaceutical wholesaler and healthcare services company, controlling ~41% of the U.S. drug distribution market. The company has transformed from a traditional distributor into a diversi...

8/ 10Strong

Cyborg Score thesis

Structural re-rating from cyclical distributor to specialty pharma/oncology play with superior margins and duopoly pricing...

Read the full analyst-debate transcript →
Industry Pharmaceutical & Medical Distribution; Healthcare Services
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest McKesson Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for McKesson Corporation

AskCyborg analysts argue the bull and bear cases for McKesson Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
McKesson Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

McKesson Corporation Overview

Pro stress-test →

McKesson is America's leading pharmaceutical wholesaler and healthcare services company, controlling ~41% of the U.S. drug distribution market. The company has transformed from a traditional distributor into a diversified healthcare platform integrating oncology services, specialty pharmaceuticals, medical-surgical solutions, and technology platforms.

Strategic Profile

Pro stress-test →

McKesson's competitive advantage rests on its dominant U.S. Oncology Network (acquired 2010), which provides integrated clinical services and supply chain capabilities unavailable to rivals. By divesting European operations (January 2026) and planning to spin off its medical-surgical segment, management is focused on high-margin specialty pharmaceutical and oncology markets where demand is accelerating.

Competitive Landscape

Pro stress-test →

McKesson faces a "Big Three" oligopoly with Cencora (35% share) and Cardinal Health (22% share). While Cencora maintains international strength, McKesson's oncology dominance and U.S.-focused strategy provide superior specialty drug positioning. The three players control >90% of U.S. pharmaceutical wholesale, creating structural pricing power and high barriers to entry.

Industry Context

McKesson Corporation operates in Pharmaceutical & Medical Distribution; Healthcare Services.

Key facts

Founded: 1833 · Headquarters: Irving, Texas · Revenue: $106.2B (Q3 FY2026 annualized) · Market cap: $92.6B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on McKesson Corporation.

  • Oncology segment is underpenetrated engine: US Oncology leads clinical trial recruitment and provides unique competitive moat rivals struggle to replicate
  • Strategic portfolio optimization underway: Medical-surgical segment planned for 2025 spin-off; European exit (Jan 2026) narrows focus to high-margin North American markets
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q3 earnings beat, EPS guidance raised to $38.80-$39.20; European divestiture completed
  • February 2026Stock surged 17% following earnings; Morgan Stanley and BofA raised price targets
  • +2 moreTrack every material event for McKesson Corporation as it happens. Explore monitoring →
Get alerted when McKesson Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CencoraSecond-largest U.S. pharma wholesaler with strong specialty services→Cardinal HealthThird-largest pharma wholesaler focused on medical-surgical and home health→US OncologyIntegrated oncology services and clinical trial platform (subsidiary)→

Compare McKesson Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

McKesson Corporation operates in Pharmaceutical & Medical Distribution; Healthcare Services. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical & Medical Distribution; Healthcare Services research →
NEW · MCP server

Ask your AI assistant about McKesson Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare McKesson Corporation and its top competitor on Cyborg Score”
“What did McKesson Corporation do this quarter?”
“Is McKesson Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does McKesson Corporation do?+
McKesson is America's leading pharmaceutical wholesaler and healthcare services company, controlling ~41% of the U.S. drug distribution market. The company has transformed from a traditional distributor into a diversi...
What is McKesson Corporation's Cyborg Score?+
McKesson Corporation has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are McKesson Corporation's main competitors?+
Named competitors include Cencora, Cardinal Health, US Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full McKesson Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the McKesson Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track McKesson Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical & Medical Distribution; Healthcare Services research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Cencora, Inc.